Literature DB >> 24961484

Hidradenitis suppurativa: the role of immune dysregulation.

Genevieve Kelly1, Cheryl M Sweeney, Anne-Marie Tobin, Brian Kirby.   

Abstract

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disease of follicular occlusion characterized by boils, sinus tracts, fistulae, and scarring. It has a significant underestimated morbidity. Antimicrobial, immunosuppressive, anti-androgenic, and surgical approaches have been used with varying results. Knowledge of the pathogenesis of HS is fragmented, and treatment choices have hitherto been empiric without an exact understanding of the scientific basis for their use. Tumor necrosis factor-α inhibitors have shown promise in the treatment of HS in recent years, and the concept of HS as an immunological condition has come to the fore. The focus of this review is to discuss the immunological abnormalities underpinning HS as elucidated to date.
© 2014 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24961484     DOI: 10.1111/ijd.12550

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  20 in total

Review 1.  Hidradenitis Suppurativa: Causes, Features, and Current Treatments.

Authors:  Caroline Vinkel; Simon Francis Thomsen
Journal:  J Clin Aesthet Dermatol       Date:  2018-10-01

2.  Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa.

Authors:  Anirban Banerjee; Sean McNish; Victoria K Shanmugam
Journal:  Immunol Invest       Date:  2016-11-07       Impact factor: 3.657

Review 3.  Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.

Authors:  Éric Toussirot; François Aubin
Journal:  RMD Open       Date:  2016-07-15

Review 4.  Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association.

Authors:  Mariabeatrice Principi; Nicoletta Cassano; Antonella Contaldo; Andrea Iannone; Giuseppe Losurdo; Michele Barone; Mario Mastrolonardo; Gino Antonio Vena; Enzo Ierardi; Alfredo Di Leo
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

5.  Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa.

Authors:  Tina Boortalary; Kanchan Misra; Sean McNish; Derek Jones; Victoria K Shanmugam
Journal:  J Dermatolog Treat       Date:  2018-01-22       Impact factor: 3.359

6.  Prevalence of antinuclear antibodies in hidradenitis suppurativa.

Authors:  Shaunak Mulani; Sean McNish; Derek Jones; Victoria K Shanmugam
Journal:  Int J Rheum Dis       Date:  2018-05       Impact factor: 2.454

7.  Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa.

Authors:  Malgorzata Ponikowska; Łukasz Matusiak; Monika Kasztura; Ewa Jankowska; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2021-09-22       Impact factor: 3.875

8.  Pathogenetic Characteristics of Mesenchymal Stem Cells in Hidradenitis Suppurativa.

Authors:  Anna Campanati; Monia Orciani; Giulia Sorgentoni; Veronica Consales; Annamaria Offidani; Roberto Di Primio
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

9.  Inherent differences in keratinocyte function in hidradenitis suppurativa: Evidence for the role of IL-22 in disease pathogenesis.

Authors:  Derek Jones; Anirban Banerjee; Peter Z Berger; Alexandra Gross; Sean McNish; Richard Amdur; Victoria K Shanmugam
Journal:  Immunol Invest       Date:  2017-10-03       Impact factor: 3.657

Review 10.  Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.

Authors:  Elena Campione; Caterina Lanna; Laura Diluvio; Maria Vittoria Cannizzaro; Sandro Grelli; Marco Galluzzo; Marina Talamonti; Margherita Annicchiarico-Petruzzelli; Mara Mancini; Gerry Melino; Eleonora Candi; Gianfranco Schiavone; Ying Wang; Yufang Shi; Luca Bianchi
Journal:  Cell Cycle       Date:  2020-01-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.